動物雙歧桿菌乳酸亞種 BB-12 Bifidobacterium animalis subsp. lactis BB-12 × 抗生素相關腹瀉
結論：證據不足
BB-12 單獨用於預防抗生素相關腹瀉（AAD）僅有極少數小型 strain-exact RCT（PMC8398419, N=62；La-5+BB-12 複方 strain-specific 統合 RR 0.
D 🔴 D 反證據 證據不足 🚨 high — heavy affiliate marketing in TW community
BB-12 單獨用於預防抗生素相關腹瀉（AAD）僅有極少數小型 strain-exact RCT（PMC8398419, N=62；La-5+BB-12 複方 strain-specific 統合 RR 0.79, 95% CI 0.47–1.33 未達顯著），證據強度遠弱於 LGG 與 S. boulardii。
ACG 2016 與 ESPGHAN/NASPGHAN 兒科指引均明文僅強烈推薦 LGG 與 S. boulardii，未將 BB-12 列為 AAD 預防的建議菌株。
Mayo Clinic、Harvard Health、Cleveland Clinic 在 AAD 情境下談益生菌時皆未指名 BB-12，屬通用級「probiotics」論述，存在明顯 strain-specificity gap。
BB-12 對腸道菌相多樣性與 SCFA 有 strain-exact 保護證據，但臨床鬆便/腹瀉終點僅為次要趨勢且樣本不足，目前最多支持「保護腸道菌相」之輔助宣稱，不應作為單獨預防 AAD 的首選。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.36
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
D · 證據不足
信心度
66%
證據方向大致一致
證據層級
E1
Cochrane 高品質系統性回顧／統合分析
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.356
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative)，由 raw_score 決定
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Probiotics for the prevention of pediatric antibiotic-associated diarrhea (Cochrane Review, Guo et al., update of CD004827.pub5)
結論：Across 33 RCTs (6352 children) probiotics cut AAD from 19% to 8% (RR 0.45, 95% CI 0.36-0.56, NNTB 9, moderate-certainty), with high-dose >=5 billion CFU/d driving the effect (RR 0.37, 95% CI 0.30-0.46); BB-12 was not analysed as a separate strain subgroup so this is all-strain context, not direct BB-12 evidence.
前往 PubMed Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients - A Systematic Review and Meta-Analysis (Blaabjerg et al., Antibiotics Basel)
結論：Pooled across 17 RCTs (3631 outpatients) probiotics cut AAD from 17.7% to 8.0% (RR 0.49, 95% CI 0.36-0.66), but the only BB-12-containing subgroup (L. acidophilus La-5 + B. lactis Bb-12) was NOT significant (RR 0.79, 95% CI 0.47-1.33), unlike LGG (RR 0.29, 95% CI 0.15-0.57) and S. boulardii (RR 0.41, 95% CI 0.30-0.57).
前往 PubMed Meta-analysis: probiotics in antibiotic-associated diarrhoea (Videlock & Cremonini, Aliment Pharmacol Ther)
結論：Across 34 double-blind RCTs (4138 patients) probiotics reduced AAD risk (RR 0.53, 95% CI 0.44-0.63, NNT 8), remaining significant across probiotic-species subgroups, but the analysis pooled at species/all-strain level and reports no standalone B. animalis lactis BB-12 effect size.
前往 PubMed Probiotic Yogurt for the Prevention of Antibiotic-associated Diarrhea in Adults: A Randomized Double-blind Placebo-controlled Trial (Velasco et al., J Clin Gastroenterol)
結論：In 314 hospitalized adults (mean age 76y) AAD occurred in 23.0% of the BB-12-containing probiotic group vs 17.6% of placebo - numerically worse - with absolute risk reduction -5.35% (95% CI -15.4% to 4.7%, p=0.30), and no difference in diarrhea duration, bowel movements, or mortality; authors concluded the LA-5/BB-12/LC-01 mix has no effect on AAD.
前往 PubMed Bifidobacterium animalis subsp. lactis BB-12 Protects against Antibiotic-Induced Functional and Compositional Changes in Human Fecal Microbiome (Merenstein et al., Nutrients)
結論：In 62 healthy adults (42 BB-12 yogurt, 20 control) on amoxicillin/clavulanate, BB-12 yogurt limited the antibiotic-induced drop in fecal acetate (recovered to -1.6% of baseline by day 30 vs sustained suppression in controls) and gave more stable Shannon diversity, but these are microbiome surrogate endpoints and the trial was not powered for, and did not demonstrate, a reduction in clinical AAD.
前往 PubMed L4a US FDA
支持
GRN 856 - Bifidobacterium animalis subsp. lactis strain BB-12; Status: FDA closure with no objections; No-Objection Letter Date: December 9, 2019; Intended Use: 'For use as an ingredient in conventional foods for use by the general population, excluding foods subject to regulation by the USDA, at levels intended to provide 5 x 10^11 CFU/serving.' Notifier: Chr. Hansen, Inc. (Milwaukee, WI). 來源↗
L4b EU EFSA
謹慎
Scientific Opinion on the substantiation of health claims related to Bifidobacterium animalis ssp. lactis Bb-12 and immune defence against pathogens (ID 863), decreasing potentially pathogenic gastro-intestinal microorganisms (ID 866), 'natural immune function' (ID 924), reduction of symptoms of inflammatory bowel conditions (ID 1469) and maintenance of normal blood LDL-cholesterol concentratio… 來源↗
L4c UK NHS
謹慎
There's some evidence that probiotics may be helpful in some cases, such as helping to ease some symptoms of irritable bowel syndrome (IBS). But there's little evidence to support many health claims made about them. For example, there's no evidence to suggest that probiotics can help treat eczema. Probiotics are generally classed as food rather than medicine, which means they don't go through t… 來源↗
L4d TW TFDA / 衛福部
中性
— 本適應症無對應資料
L4e WHO
中性
— 本適應症無對應資料
L5a NIH Office of Dietary Supplements
支持
The BB-12 Bifidobacterium animalis subsp. lactis strain is one of the most documented probiotic strains on the market and has been shown to be effective in alleviating symptoms of a low defecation frequency and infant colic, among others. The strain has been granted GRAS (generally recognized as safe) status in the United States, and the species has QPS (qualified presumption of safety) status … 來源↗
L5b Mayo Clinic
謹慎
Some people take supplements called probiotics to restore the balance of healthy bacteria in their guts. But the research is mixed on whether probiotics ease symptoms of antibiotic-associated diarrhea. Taking probiotics probably won't do harm, but people with weakened immune systems should not use probiotic supplements. 來源↗
L5c Cleveland Clinic
支持
The most commonly studied for antibiotic-associated diarrhea are Lactobacillus rhamnosus-based and Saccharomyces boulardii-based probiotics. The thing that has really been shown to help the most with preventing diarrhea is taking probiotics when taking antibiotics. Probiotics could possibly be harmful for people with immune deficiencies or those who are severely debilitated. 來源↗
L5d Harvard Health
中性
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
中性
For the prevention of antibiotic-associated diarrhea (AAD) in children, the guideline recommends using Lactobacillus rhamnosus GG (moderate quality of evidence, strong recommendation) or Saccharomyces boulardii (moderate quality of evidence, strong recommendation). The recommendations were formulated only if at least 2 randomized controlled trials using a given probiotic with strain specificati… 來源↗
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽
台灣社群（PTT、Dcard、Mobile01、BabyHome）中針對 BB-12 菌株與抗生素相關腹瀉的具體討論極少，多為通稱「益生菌」搭配抗生素的籠統建議，並未指名 Chr Hansen BB-12；少數有指名菌株者多為妙利散（CBM-588）或 LGG，而非 BB-12，因此本配對在 TW 社群屬「資料不足」、非菌株專屬討論。
💬社群實感
資料不足
破解迷思 社群最常見的 3 個誤解
✓
事實誤以為任何益生菌都能與抗生素同時併服而不影響效果
✓
事實將 BB-12 與優酪乳/養樂多日常乳酸菌效用混為一談
✓
事實認為標榜「丹麥科漢森菌株」就一定是 BB-12，忽略還有 LA-5、BB-46 等其他菌株
🩹 社群通報的副作用
- 初期脹氣
- 排便型態短暫改變
🏷️ 社群熱議品牌
依論壇被提及頻率，非銷售或品質排序。
- 妙利散 (Miya-San / CBM-588)
- 欣表飛鳴
- Culturelle (LGG)
- 養樂多 (LcS)
- 威德益生菌
- 好市多販售之綜合益生菌
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 停用或調整抗生素
- 口服補液 + 益生菌 (Saccharomyces boulardii / LGG)
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-antibiotic-associated-diarrhea-INT-bifidobacterium-animalis-bb-12-001/",
"datePublished": "2026-06-09",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "動物雙歧桿菌乳酸亞種 BB-12能改善抗生素相關腹瀉",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 1,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🔴 D 反證據"
}
}